Multiple myeloma Pipeline Drugs and Companies Insight Report (2022): Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments

Multiple myeloma Overview

Multiple myeloma (MM) is a clonal plasma cell proliferative disorder characterized by the abnormal increase of monoclonal immunoglobulins. Unchecked, the excess production of these plasma cells can ultimately lead to specific end-organ damage. Most commonly, this is seen when at least one of the following clinical manifestations are present: hypercalcemia, renal dysfunction, anemia, or bone pain accompanied by lytic lesions.

“Multiple myeloma Pipeline Insight, 2022“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Multiple myeloma Market.

The Multiple myeloma Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details. 

Some of the key takeaways from the Multiple myeloma Pipeline Report:

• Companies across the globe are diligently working toward developing novel Multiple myeloma treatment therapies with a considerable amount of success over the years. Multiple myeloma Key players such as – BRL Medicine, Poseida Therapeutics, ImmuneCyte, Ionis Pharmaceuticals, CASI Pharmaceuticals, Sorrento Therapeutics, Cartesian Therapeutics, Rapa Therapeutics, Novartis, I-MAB Biopharma, AbbVie, Pfizer, and others, are developing therapies for the Multiple myeloma treatment 

• Multiple myeloma Emerging therapies such as – BRL 202, P-BCMACD19-ALLO1, IMC 3253, ION251, CID-103, STI-1492, Descartes 08, RAPA-201, PHE885, TJ202, Venetoclax, Elranatamab, and others are expected to have a significant impact on the Multiple myeloma market in the coming years.    
• In December 2021, the US FDA and the EMA had granted orphan drug designations to elranatamab, for the treatment of multiple myeloma. The EMA also has granted Priority Medicine (PRIME) status to the drug for multiple myeloma
• In March 2022, Pfizer initiated a randomized, 2-arm, Phase III study of Elranatamab (PF-06863135)versus Lenalidomide in patients with newly diagnosed multiple myeloma who are minimal residual disease positive after undergoing autologous stem-cell transplantation

Multiple myeloma Pipeline Therapeutics Assessment

• Multiple myeloma Assessment by Product Type
• Multiple myeloma By Stage and Product Type
• Multiple myeloma Assessment by Route of Administration
• Multiple myeloma By Stage and Route of Administration
• Multiple myeloma Assessment by Molecule Type
• Multiple myeloma by Stage and Molecule Type

DelveInsight’s Multiple myeloma Report covers around 130+ products under different phases of clinical development like

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration 

Emerging Multiple myeloma Drugs Under Different Phases of Clinical Development Include:

• BRL 202: BRL Medicine
• P-BCMACD19-ALLO1: Poseida Therapeutics
• IMC 3253: ImmuneCyte
• ION251: Ionis Pharmaceuticals
• CID-103: CASI Pharmaceuticals
• STI-1492: Sorrento Therapeutics
• Descartes 08: Cartesian Therapeutics
• RAPA-201: Rapa Therapeutics
• PHE885: Novartis
• TJ202: I-MAB Biopharma
• Venetoclax: AbbVie
• Elranatamab: Pfizer 

Get a Free Sample PDF Report to know more about Multiple myeloma Pipeline Assessment- https://www.delveinsight.com/sample-request/multiple-myeloma-pipeline-insight

Multiple myeloma Pipeline Analysis:

The Multiple myeloma pipeline report provides insights into 

• The report provides detailed insights about companies that are developing therapies for the Multiple myeloma treatment with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Multiple myeloma Treatment.
• Multiple myeloma key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Multiple myeloma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Multiple myeloma market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Further Multiple myeloma product details are provided in the report. Download the Multiple myeloma pipeline report to learn more about the emerging Multiple myeloma therapies

Multiple myeloma Pipeline Market Drivers

• Rising prevalence of multiple myeloma worldwide
• Increasing investment for healthcare infrastructure
• Introduction of monoclonal antibodies with safety profile to fight myeloma cells

Multiple myeloma Pipeline Market Barriers

• High cost associated with the treatment of multiple myeloma
• Lack of healthcare infrastructure in developing economies

Scope of Multiple myeloma Pipeline Drug Insight    

• Coverage: Global
• Key Multiple myeloma Companies: BRL Medicine, Poseida Therapeutics, ImmuneCyte, Ionis Pharmaceuticals, CASI Pharmaceuticals, Sorrento Therapeutics, Cartesian Therapeutics, Rapa Therapeutics, Novartis, I-MAB Biopharma, AbbVie, Pfizer, and others
• Key Multiple myeloma Therapies: BRL 202, P-BCMACD19-ALLO1, IMC 3253, ION251, CID-103, STI-1492, Descartes 08, RAPA-201, PHE885, TJ202, Venetoclax, Elranatamab, and others
• Multiple myeloma Therapeutic Assessment: Multiple myeloma current marketed and Multiple myeloma emerging therapies
• Multiple myeloma Market Dynamics: Multiple myeloma market drivers and Multiple myeloma market barriers 

Request for Sample PDF Report for Multiple myeloma Pipeline Assessment and clinical trials

Table of Contents

Download Sample PDF Report to know more about Multiple myeloma drugs and therapies 

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/